Table 2.
General characteristics of included studies in the meta-analysis.
| Author/Year | Country | Study design | Population | Sample Size (Cont/Int) |
Age | Gender | Intervention/Dose | Dose | Duration | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Kahodom Mohson et al., 2021 (16) | Iraq | Quasi-experimental non-randomized |
T2DM | 40 (20/20) |
31–57 | M:24 F:16 |
Boswellia powder 1200 mg/day |
1200 (mg/day) | 12 weeks | HbA1C, TC, TG, HDL. LDL, |
| Mehrzadi et al. 2018 (15) |
Iran | RCT | T2DM | 56 (29/27) |
18–65 | M:26 F:30 |
Boswellia gum resin 500 mg/day |
500 (mg/day) | 8 weeks | FBG, HbA1C, TC, TG, HDL. LDL, |
| Khalili et al. 2017 (14) |
Iran | RCT | T2DM | 60 (30/30) |
40–60 | M:30 F:30 |
Boswellia gum resin 600 mg/day |
600 (mg/day) | 12 weeks | FBG, HbA1C, |
| Ahangarpour et al. 2014 (12) |
Iran | RCT | T2DM | 60 (30/30) |
30–48 | M:30 F:30 |
Boswellia gum resin 900 mg/day |
900 (mg/day) | 6 weeks | TC, TG, HDL. LDL, |
| Azadmehra et al. 2014(13) |
Iran | RCT | T2DM | 71 (34/37) |
18–65 | M:42 F:29 |
Boswellia resin 800 mg/day |
800 (mg/day) | 12 weeks | FBG, HbA1C, TC, TG. LDL, |
Cont, control; Int, intervention; RCT, Randomized controlled trial; T2DM, Type 2 Diabetes mellitus; M, male; F, female.